权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF

使用新型生物 ELP-VEGF 进行肾脏治疗性血管生成

基本信息

批准号：
10705193
负责人：
Gene Leflore Bidwell
金额：
$ 96.08万
依托单位：
LEFLORE TECHNOLOGIES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10705193
关键词：
3-Dimensional Adverse effects Affect Affinity Aging Angioplasty Angiotensins Animals Architecture Binding Biological Biological Assay Biological Availability Biomedical Engineering Biopolymers Blood Vessels Breast Cancer Model Canis familiaris Cardiovascular system Carrier Proteins Cessation of life Chemistry Chimeric Proteins Chronic Chronic Kidney Failure Clinical Deterioration Diabetes Mellitus Dialysis procedure Diet Disease Disease model Dose Drug Carriers Dyslipidemias Elastin End stage renal failure Endothelium Engineering Etiology Funding Future General Population Glomerular Filtration Rate Goals Good Manufacturing Process Growth Growth Factor Half-Life Health Care Costs Histologic Hospitalization Human Hypertension Injury to Kidney Kidney Kidney Diseases Laboratories Lead Life Expectancy Link Marketing Maximum Tolerated Dose Mediating Microcirculation Miniature Swine Modeling Morbidity - disease rate Mus Myocardial Infarction Nature Patients Pharmaceutical Preparations Pharmacology Study Phase Plasma Preclinical Testing Predisposition Prevalence Process Production Proteins Protocols documentation Quality Control Rattus Recombinants Recovery Renal Artery Stenosis Renal Blood Flow Renal Vascular Disorder Renal function Research Contracts Resolution Risk Rodent Rodent Model Safety Serious Adverse Event Severity of illness Small Business Technology Transfer Research Stents Stroke Technology Testing Therapeutic Time Tissues Toxicity Tests Toxicology Treatment Efficacy Treatment Protocols Tubular formation United States VEGFA gene Validation Vascular Endothelial Growth Factors Work X-Ray Computed Tomography Xenograft Model angiogenesis biomaterial compatibility cardiovascular risk factor clinically relevant cohort density efficacy study efficacy testing good laboratory practice hospitalization rates immunogenicity improved in vivo kidney vascular structure manufacture mortality novel novel therapeutics patient population peptide drug phase 1 study phase 2 study polypeptide porcine model pre-clinical preclinical trial renal artery renal damage residence response safety study side effect small molecule therapeutic angiogenesis therapeutic development therapeutic protein treatment arm tumor growth

项目摘要

Abstract. Chronic kidney disease (CKD) is a progressive disorder affecting almost 14% of the general population, and this disease has shown a relentless growth over the past 2 decades. Patients with CKD have higher rates of hospitalization, greater mortality, shorter life expectancy, and their healthcare costs are up to 5 times more expensive than non-CKD patients. Thus, treatments to slow, halt, or reverse the progression of CKD could have a significant financial and clinical impact. Chronic renal vascular disease (RVD), often associated with renal artery stenosis, can deteriorate renal function and lead to CKD and end-stage renal disease in up to 15% of patients. Despite the availability of treatments for RVD including drugs and percutaneous transluminal renal angioplasty, renal function does not improve or even deteriorates in over half of the patients undergoing these treatments. Leflore Technologies has developed a biopolymer-stabilized form of vascular endothelial growth factor (VEGF) with high renal binding. Leflore Technology’s overall strategy is to use the biopolymer-VEGF fusion for therapeutic angiogenesis to restore renal microvasculature and improve renal function in RVD and/or CKD. During the Phase I portion of this STTR, non-GLP efficacy and toxicity testing were conducted with the biopolymer-fused VEGF. Using a swine model of renal artery stenosis – induced RVD, angioplasty and stenting with or without therapeutic renal angiogenesis using our biopolymer-stabilized VEGF was tested in a preclinical trial. In the treatment arm, renal function and renal vascular density were significantly improved, and histological markers of renal injury were reduced, relative to angioplasty and stenting alone. We also performed a dose- escalating toxicology study in rats, which demonstrated that the biopolymer-stabilized VEGF induced no significant side-effects at doses up to 100 times the planned therapeutic dose. The proposed Phase II studies will advance the lead agent through cGMP manufacturing; chemistry, manufacturing and controls testing; and expanded preclinical IND-enabling GLP toxicology. The planned studies will also extend our prior efficacy studies by testing in animals with progressively more severe renal disease, with longer follow-ups, and using multiple rodent models of CKD caused by diabetes or hypertension as well as extended studies in our translational swine model of CKD to expand the potential target market beyond RVD treated with stenting to chronic kidney disease as a whole.

抽象的。慢性肾脏疾病（CKD）是一种进行性疾病，影响近14%的普通人群，这种疾病在过去20年中呈无情增长趋势。CKD患者的发病率较高，住院、死亡率更高、预期寿命更短，他们的医疗保健费用高达5倍比非CKD患者更昂贵。因此，减缓、停止或逆转CKD进展的治疗可能具有以下作用：一个重大的经济和临床影响。慢性肾血管疾病（RVD），通常与肾动脉狭窄，可恶化肾功能，导致CKD和终末期肾病，患者尽管RVD的治疗方法可用，包括药物和经皮腔内肾移植，尽管有血管成形术，但在接受这些手术的患者中，超过一半的患者的肾功能没有改善甚至恶化。治疗。莱弗洛雷科技公司开发了一种生物聚合物稳定的血管内皮生长形式高肾结合因子（VEGF）。莱弗洛雷科技公司的总体战略是利用生物聚合物--VEGF 用于治疗性血管生成的融合，以恢复RVD中的肾微血管并改善肾功能，和/或慢性肾脏病。在本STTR的I期部分，使用以下药物进行了非GLP疗效和毒性试验：生物聚合物融合的VEGF。采用猪肾动脉狭窄模型诱导RVD，血管成形术和支架植入术使用我们的生物聚合物稳定的VEGF进行治疗性肾血管生成或不进行治疗性肾血管生成，审判在治疗组中，肾功能和肾血管密度显著改善，相对于单独的血管成形术和支架植入术，肾损伤的标记物减少。我们还做了一个剂量- 在大鼠中进行的逐步增加的毒理学研究表明，生物聚合物稳定的VEGF不会诱导在高达计划治疗剂量100倍的剂量下出现显著副作用。拟议的II期研究将通过cGMP生产、化学、生产和控制测试推进先导药物;以及扩展临床前IND使能GLP毒理学。计划中的研究还将扩展我们先前的疗效通过在患有进行性更严重肾脏疾病的动物中进行测试，进行更长时间的随访，并使用糖尿病或高血压引起的CKD的多种啮齿类动物模型以及我们的扩展研究 CKD的转化猪模型，以将潜在目标市场扩展到用支架治疗的RVD之外，慢性肾脏疾病的整体。